✦ LIBER ✦

Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the Bladder

✍ Scribed by D. M. A. WALLACE; D. RAGHAVAN; K. A. KELLY; T. F. SANDEMAN; I. G. CONN; N. TERIANA; J. DUNN; J. BOULAS; T. LATIEF

Book ID: 115196422
Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 654 KB
Volume: 67
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.1991.tb15225.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P013 Outcomes of selective bladder prese

P013 Outcomes of selective bladder preservation with neo-adjuvant chemotherapy in muscle invasive transitional cell carcinoma (TCC)

✍ Hafeez, S.; Huddart, R.A. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

PCN11 COST EFFECTIVENESS OF ADJUVANT, IN

PCN11 COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL THERAPY FOR NON-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER

✍ M Kerrigan; SD Ramsey; D Penson; DK Blough; L Garrison 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

ADJUVANT GEMCITABINE-CISPLATIN CHEMOTHER

ADJUVANT GEMCITABINE-CISPLATIN CHEMOTHERAPY OF INVASIVE TRANSITIONAL CELL CARCINOMA OF THE UPPER URINARY TRACT

✍ Song, Yun Seob; Yun, Jong Hyun; Yang, Won Jae; Doo, Seung Hwan; Kim, Chun; Kim, 📂 Article 📅 2008 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 123 KB

1142 Neo-adjuvant M-VAC chemotherapy and

1142 Neo-adjuvant M-VAC chemotherapy and bladder preservation for muscle infiltrating transitional cell carcinoma (TCC) of the bladder

✍ Sternberg, C.; Pansadora, V.; Lauretti, S.; Platania, A.; Giannarelli, D.; Rosse 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 154 KB

PTCH gene mutations in invasive transiti

PTCH gene mutations in invasive transitional cell carcinoma of the bladder

✍ McGarvey, Terence W; Maruta, Yuhgo; Tomaszewski, John E; Linnenbach, Alban J; Ma 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 458 KB

Adjuvant Bestatin immunotherapy in patie

Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder

✍ Henric Blomgren; Ingemar Näslund; Pier-Luigi Esposti; Lise Johansen; Ove Aaskove 📂 Article 📅 1987 🏛 Springer-Verlag 🌐 English ⚖ 554 KB

The first clinical results of an ongoing, prospective trial to determine the value of adjuvant Bestatin immunotherapy in the management of bladder cancer are presented. Patients with nonmetastatic transitional cell carcinoma of the bladder, scheduled for full dose local radiation therapy (64 Gy), we